Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity
Executive Summary
Morphine sulfate extended-release product’s approval with only one of three routes of abuse raises questions about how effectively US FDA’s policies are encouraging development of abuse-deterrent opioid formulations.
You may also be interested in...
KemPharm And The Curious Case Of Launching A Brand Opioid Like A Generic
KemPharm is looking to sign a generic drug partner to launch its new brand opioid Apadaz, which says a lot about how the commercial promise of abuse-deterrent opioids has so far failed to materialize.
KemPharm And The Curious Case Of Launching A Brand Opioid Like A Generic
KemPharm is looking to sign a generic drug partner to launch its new brand opioid Apadaz, which says a lot about how the commercial promise of abuse-deterrent opioids has so far failed to materialize.
Abuse-Deterrent Opioids: Rexista To Test New FDA Leadership's Approach
Intellipharmaceutics seeks oral, intranasal and intravenous abuse-deterrence claims for Rexista (extended-release oxycodone) when it goes before an advisory committee July 26. Even if it passes muster with the US agency under Commissioner Scott Gottlieb, patent and exclusivity issues could impact market availability and labeling.